Author:
Beumont P.,Bruwer J.,Pimstone B.,Vinik A.,Utian W.
Abstract
An ergot alkaloid, 2-br-alpha-ergocryptine (CB 154), referred to hereafter as brom-ergocryptine, has been reported to inhibit puerperal lactation (Varga, Lutterbeck et al., 1972), and to terminate breast secretion in patients with inappropriate lactation (Lutterbeck, Pryor et al., 1971). Besser, Park et al. (1972) found that the drug suppressed elevated levels of plasma prolactin in five patients whose inappropriate lactation was due to a variety of causes. This hormonal effect was accompanied by clinical changes such as the disappearance of galactorrhoea, return of menstruation, and an increase in sexual potency.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Reference8 articles.
1. Do Psychiatric In-Patients Take their Pills?
2. Endocrine profiles of a specific prolactin inhibitor: Br-ergocryptine (CB 154);Del Pozo;Schweizer Medizinische Wochenschaft,1973
3. Treatment of Non-puerperal Galactorrhoea with an Ergot Alkaloid
4. Treatment of galactorrhoea-amenorrhoea syndrome with br-ergocryptine (CB 154). Restoration of ovulatory function and fertility;Varoa;American Journal of Obstetrics and Gynaecology,1973
5. Suppression of puerperal lactation with an ergot alkaloid: a double-blind study;Varga;British Medical Journal,1972
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献